Anavex Life Sciences Announces Positive Results From ANAVEX 2-73 Study For Rett Syndrome Treatment

(RTTNews) - Anavex Life Sciences Corp. (AVXL) Monday announced positive results from the U.S. Phase 2 study of ANAVEX 2-73 (blarcamesine), the company's drug candidate for the treatment of female adults with Rett syndrome.

Treatment with ANAVEX 2-73 resulted in increase in the mRNA expression of SIGMAR1, that significantly correlated with improvements in the two primary clinical efficacy endpoints, the company said.

Rett syndrome is a chronic Central nervous system (CNS) disease caused by a spontaneous mutation of one gene, MECP2.

The company said it is planning to meet with the FDA to discuss the approval pathway for ANAVEX 2-73.